CARDALIS- spironolactone and benazepril hydrochloride tablet, chewable

국가: 미국

언어: 영어

출처: NLM (National Library of Medicine)

유효 성분:

SPIRONOLACTONE (UNII: 27O7W4T232) (SPIRONOLACTONE - UNII:27O7W4T232), BENAZEPRIL HYDROCHLORIDE (UNII: N1SN99T69T) (BENAZEPRILAT - UNII:JRM708L703)

제공처:

Ceva Sante Animale

관리 경로:

ORAL

처방전 유형:

PRESCRIPTION

치료 징후:

CARDALIS is indicated with concurrent therapy (e.g. furosemide, etc.) for the management of clinical signs of mild, moderate, or severe congestive heart failure in dogs due to atrioventricular valvular insufficiency (AVVI). Do not administer CARDALIS in conjunction with non-steroidal anti-inflammatory drugs (NSAIDs) in dogs with renal insufficiency. Do not administer CARDALIS to dogs with hypoadrenocorticism (Addison’s Disease), hyperkalemia, or hyponatremia. Do not administer CARDALIS to animals with known hypersensitivity to ACE inhibitors or spironolactone.

제품 요약:

CARDALIS chewable tablets for dogs are available in 3 sizes of oblong half scored flavored tablets: 20 mg spironolactone and 2.5 mg benazepril hydrochloride, 40 mg spironolactone and 5 mg benazepril hydrochloride, and 80 mg spironolactone and 10mg benazepril hydrochloride. Each size is available in 30-count bottles enclosed in color coded packages.

승인 상태:

New Animal Drug Application

제품 특성 요약

CARDALIS- SPIRONOLACTONE AND BENAZEPRIL HYDROCHLORIDE TABLET, CHEWABLE
CEVA SANTE ANIMALE
----------
CARDALIS™
(spironolactone and benazepril hydrochloride chewable tablets)
Cardiac drug for oral use in dogs only
Approved by FDA under NADA # 141-538
CAUTION: Federal (USA) law restricts this drug to use by or on the
order of a licensed
veterinarian.
DESCRIPTION:
CARDALIS (spironolactone and benazepril hydrochloride chewable
tablets) for dogs
contains two active ingredients, spironolactone and benazepril
hydrochloride, in a fixed
ratio of 8:1 respectively. CARDALIS is supplied as oblong half scored
flavored chewable
tablets in three sizes:
20 mg spironolactone and 2.5 mg benazepril hydrochloride, 40 mg
spironolactone and 5
mg benazepril hydrochloride, and 80 mg spironolactone and 10 mg
benazepril
hydrochloride.
Benazepril belongs to the angiotensin-converting enzyme (ACE)
inhibitor class of drugs.
Benazepril hydrochloride empirical formula is C
H
N O · HCl and the molecular weight
is 460.95. The chemical name is
3-[[1-(ethoxy-carbonyl)-3-phenyl-(1S)-propyl]amino]-
2,3,4,5-tetrahydro-2-oxo-1H-1-(3S)-benazepine-1-acetic acid
monohydrochloride and
the structural formula is shown below:
Spironolactone, and its active metabolites, act as specific
aldosterone antagonists.
Spironolactone empirical formula is C
H
O S and the molecular weight is 416.57. The
chemical name is
17-hydroxy-7α-mercapto-3-oxo-17α-pregn-4-ene-21-carboxylic acid
y-lactone acetate and the structural formula is shown below:
24
28
2
5
24
32
4
INDICATIONS:
CARDALIS is indicated with concurrent therapy (e.g. furosemide, etc.)
for the
management of clinical signs of mild, moderate, or severe congestive
heart failure in
dogs due to atrioventricular valvular insufficiency (AVVI).
DOSAGE AND ADMINISTRATION:
CARDALIS administration should begin after pulmonary edema is
stabilized. CARDALIS
should be administered orally once daily at a dose of 0.9 mg/lb (2
mg/kg) spironolactone
and 0.11 mg/lb (0.25 mg/kg) benazepril hydrochloride, according to dog
body we